The DOI matches its Crossref record; 130 of the 140 references it cites were found in a registry or an index.
COVID-19 cytokine storm: The anger of inflammation
Open accessAbstract
Patients with COVID-19 who require ICU admission might have the cytokine storm. It is a state of out-of-control release of a variety of inflammatory cytokines. The molecular mechanism of the cytokine storm has not been explored extensively yet. The attachment of SARS-CoV-2 spike glycoprotein with angiotensin-converting enzyme 2 (ACE2), as its cellular receptor, triggers complex molecular events that leads to hyperinflammation. Four molecular axes that may be involved in SARS-CoV-2 driven inflammatory cytokine overproduction are addressed in this work. The virus-mediated down-regulation of ACE2 causes a burst of inflammatory cytokine release through dysregulation of the renin-angiotensin-aldosterone system (ACE/angiotensin II/AT1R axis), attenuation of Mas receptor (ACE2/MasR axis), increased activation of [des-Arg9]-bradykinin (ACE2/bradykinin B1R/DABK axis), and activation of the complement system including C5a and C5b-9 components. The molecular clarification of these axes will elucidate an array of therapeutic strategies to confront the cytokine storm in order to prevent and treat COVID-19 associated acute respiratory distress syndrome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Among them, IL-6 is a major player in chronic inflammatory diseases, autoimmune diseases, cancer and cytokine storm (1, 3, 10–26).”
From IL-6 in inflammation, autoimmunity and cancer (2021) · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Therefore, SARS-CoV-1 and SARS-CoV-2 infection activate both NF-κB and STAT3, key elements of the IL-6 Amp, to cause cytokine storm (12, 13, 15, 349, 350).”
From IL-6 in inflammation, autoimmunity and cancer (2021) · cites this paper as [13]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“ARDS in COVID-19 is considered the result of cytokine storm (12–17), resembling the disease caused by SARS-CoV-1 and Middle East respiratory syndrome coronavirus (MERS-CoV) (335).”
From IL-6 in inflammation, autoimmunity and cancer (2021) · cites this paper as [13]
The cited source says what the claim attributes to it.
In the citing paper
“Consistent with the notion that severe COVID-19 is a cytokine storm syndrome (12–17, 336), the severity of COVID-19 is associated with an increased level of inflammatory cytokines, such as IL-6, granulocyte macrophage colony-stimulating factor (GM-CSF) and TNFα (333, 337).”
From IL-6 in inflammation, autoimmunity and cancer (2021) · cites this paper as [13]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884
Pathological findings of COVID-19 associated with acute respiratory distress syndrome
Xu, Z., Shi, L., Wang, Y., Zhang, J., Huang, L., Zhang, C., Liu, S., Zhao, P., Liu, H., Zhu, L., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30076-x · Cited by 8,545 · cited 9×
“An increment of the highly pro-inflammatory CCR6+ Th17 in CD4 T cells was reported in COVID-19 associated with ARDS [9].”
InfluentialStructure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor
Lan, J., Ge, J., Yu, J., Shan, S., Zhou, H., Fan, S., Zhang, Q., Shi, X., Wang, Q., Zhang, L., et al. (2020) · Nature · doi:10.1038/s41586-020-2180-5 · Cited by 5,983 · cited 3×
“These severe cases that develop respiratory failure show a series of pathological findings such as hyaline membrane formation, inflammatory infiltration with multinucleated syncytial cells in their lung pathology and a burst of cytokine release leading to morbidity and mortality [6,12].”
Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study
Chen, T., Wu, D., Chen, H., Yan, W., Yang, D., Chen, G., Ma, K., Xu, D., Yu, H., Wang, H., et al. (2020) · BMJ · doi:10.1136/bmj.m1091 · Cited by 3,903
Emerging coronaviruses: Genome structure, replication, and pathogenesis
Chen, Y. Z., Liu, Q., & Guo, D. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25681 · Cited by 3,069
Angiotensin-converting enzyme 2 protects from severe acute lung failure
Imai, Y., Kuba, K., Rao, S., Huan, Y., Guo, F., Guan, B., Yang, P., Sarao, R., Wada, T., Leong-Poi, H., et al. (2005) · Nature · doi:10.1038/nature03712 · Cited by 2,453 · cited 1×
“The protective effect of ACE2 in severe acute lung failure has been shown in animal models [40].”
Ziegler, C. G. K., Allon, S. J., Nyquist, S. K., Mbano, I. M., Miao, V. N., Tzouanas, C. N., Cao, Y., Yousif, A. S., Bals, J., Hauser, B. M., et al. (2020) · Cell · doi:10.1016/j.cell.2020.04.035 · Cited by 2,284 · cited 2×
“ACE2 enzyme is expressed in the heart, kidneys, testes, gastrointestinal tract and lungs [15,31].”
MAGRO, C. M. J., Mulvey, J. J., Berlin, D., Nuovo, G. J., Salvatore, S., Harp, J., Baxter-Stoltzfus, A., & Laurence, J. C. (2020) · Translational research · doi:10.1016/j.trsl.2020.04.007 · Cited by 2,224 · cited 1×
“[112] reported a pauci-inflammatory changes and lack of viral cytopathic effects accompanied with heavy deposition of C5b-9, C4d and MBL-MASP2 in lung septal vasculatures of 5 patients with”
Monteil, V., Kwon, H., Prado, P., Hagelkrüys, A., Wimmer, R. A., Stahl, M., Leopoldi, A., Garreta, E., Hurtado del Pozo, C., Prosper, F., et al. (2020) · Cell · doi:10.1016/j.cell.2020.04.004 · Cited by 2,122
Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19
Vaduganathan, M., Vardeny, O., Michel, T., McMurray, J. J. V., Pfeffer, M. A., & Solomon, S. D. (2020) · New England Journal of Medicine · doi:10.1056/nejmsr2005760 · Cited by 2,101
Liu, Y., Yang, Y., Zhang, C., Huang, F., Wang, F., Yuan, J., Wang, Z., Li, J., Li, J., Feng, C., et al. (2020) · Science China Life Sciences · doi:10.1007/s11427-020-1643-8 · Cited by 2,056 · cited 1×
“fact, higher circulatory levels of Ang II were reported in COVID-19 patients than the control subjects and these plasma levels of Ang II were linearly associated with lung injury [36].”
Into the Eye of the Cytokine Storm
Tisoncik, J. R., Korth, M. J., Simmons, C. P., Farrar, J., Martin, T. R., & Katze, M. G. (2012) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.05015-11 · Cited by 1,940
Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system
Mehta, P. K., & Griendling, K. K. (2007) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00287.2006 · Cited by 1,924
Mitogen-activated protein kinases in innate immunity
Arthur, J. S. C., & Ley, S. C. (2013) · Nature reviews. Immunology · doi:10.1038/nri3495 · Cited by 1,898
Gheblawi, M., Wang, K., Viveiros, A., Nguyen, Q., Zhong, J.-C., Turner, A. J., Raizada, M. K., Grant, M. B., & Oudit, G. Y. (2020) · Circulation Research · doi:10.1161/circresaha.120.317015 · Cited by 1,882
MAP Kinases in the Immune Response
Dong, C., Davis, R. J., & Flavell, R. A. (2002) · Annual Review of Immunology · doi:10.1146/annurev.immunol.20.091301.131133 · Cited by 1,684
Hydrolysis of Biological Peptides by Human Angiotensin-converting Enzyme-related Carboxypeptidase
Vickers, C., Hales, P., Kaushik, V. K., Dick, L. R., Gavin, J. M., Tang, J., Godbout, K., Parsons, T. F., Baronas, E., Hsieh, F., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m200581200 · Cited by 1,406 · cited 14×
“The active products of this system interact with two distinct G-protein coupled receptors, the bradykinin B1 receptor (BKB1R) and bradykinin B2 receptor (BKB2R); the main ligand of BKB1R is DABK and the ligand of BKB2R is BK [69,70].”
InfluentialPlasma inflammatory cytokines and chemokines in severe acute respiratory syndrome
Wong, C. K., LAM, C. W. K., Wu, A. K. L., Ip, W., Lee, N. L. S., Chan, I., Lit, L. C. W., Hui, D. S. C., Chan, M. H. M., CHUNG, S. S. C., et al. (2004) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2004.02415.x · Cited by 1,270
The pivotal link between ACE2 deficiency and SARS-CoV-2 infection
Verdecchia, P., Cavallini, C., Spanevello, A., & Angeli, F. (2020) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2020.04.037 · Cited by 1,237 · cited 1×
“Because Ang-(1–7) exerts a critical role in counteracting the pro-inflammatory effect of RAAS, protecting from endothelial cell activation and resulting lung damage from inflammatory mediators in the cytokine storm, the administration of Ang(1–7) or one of its similar agents to patients with COVID-19 pneumonitis has b…”
The ACE2/angiotensin-(1-7)/MAS Axis of the renin-angiotensin system: focus on angiotensin-(1-7)
Santos, R. A. S., Sampaio, W. O., Alzamora, A. C., Motta-Santos, D., Alenina, N., Bader, M., & Campagnole-Santos, M. J. (2018) · Physiological Reviews · doi:10.1152/physrev.00023.2016 · Cited by 1,144 · cited 11×
“The loss of the modulatory effect of angiotensin-(1–7) via its binding to the Mas receptor (MasR) that attenuates inflammatory response may be a further contributing factor to the hyper-inflammation status of severe cases of COVID-19.”
InfluentialROLE OF C5A IN INFLAMMATORY RESPONSES
Guo, R., & Ward, P. A. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115835 · Cited by 1,026
COVID-19, ACE2, and the cardiovascular consequences
South, A. M., Diz, D. I., & Chappell, M. C. (2020) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00217.2020 · Cited by 797
TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib
Wu, D., & Yang, X. O. (2020) · Journal of Microbiology Immunology and Infection · doi:10.1016/j.jmii.2020.03.005 · Cited by 792 · cited 2×
“Therefore, targeting IL-17 and T helper 17 responses in the cytokine storm of COVID19 have been suggested [8,118].”
Rother, R. P., Rollins, S. A., Mojcik, C. F., Brodsky, R. A., & Bell, L. (2007) · Nature Biotechnology · doi:10.1038/nbt1344 · Cited by 778 · cited 1×
“Eculizumab is a monoclonal antibody with high affinity to C5 near its cleavage site [128].”
COVID-19: a new virus, but a familiar receptor and cytokine release syndrome
Hirano, T., & Murakami, M. (2020) · Immunity · doi:10.1016/j.immuni.2020.04.003 · Cited by 772
The role of the anaphylatoxins in health and disease
Klos, A., Tenner, A. J., Johswich, K.-O., Ager, R. R., Reis, E. S., & Köhl, J. (2009) · Molecular Immunology · doi:10.1016/j.molimm.2009.04.027 · Cited by 730
Complement Activation Contributes to Severe Acute Respiratory Syndrome Coronavirus Pathogenesis
Gralinski, L. E., Sheahan, T. P., Morrison, T. E., Menachery, V. D., Jensen, K., Leist, S. R., Whitmore, A. C., Heise, M. T., & Baric, R. S. (2018) · mBio · doi:10.1128/mbio.01753-18 · Cited by 656 · cited 2×
“[109] showed that mice models deficient in C3(C3-/) loads in the lung had milder SARS-CoV induced pathologic features such as better respiratory function, lower weight loss, reduced pathologic findings in respiratory system, and lower circulatory and tissue cytokines and chemokines, despite equal lung viral loads comp…”
Meng, J., Xiao, G., Zhang, J., He, X., Ou, M., Bi, J., Yang, R., Di, W., Wang, Z., Li, Z., et al. (2020) · Emerging Microbes & Infections · doi:10.1080/22221751.2020.1746200 · Cited by 619
Marceau, F., Hess, J. F., & Bachvarov, D. R. (1998) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01371-1 · Cited by 604 · cited 1×
“It should be mentioned that IL-1B and TNFα-induced BKB1R expression is related to NF-κB activity [81].”
MERS-CoV infection in humans is associated with a pro-inflammatory Th1 and Th17 cytokine profile
Mahallawi, W. H., Khabour, O. F., Zhang, Q., Makhdoum, H., & Suliman, B. A. (2018) · Cytokine · doi:10.1016/j.cyto.2018.01.025 · Cited by 563 · cited 1×
“In fact, higher concentrations of granulocyte-colony stimulating factor (G-CSF), interferon gamma-induced protein 10 (IP10), monocyte chemoattractant protein 1 (MCP1), macrophage inflammatory protein 1alpha (MIP1A), and tumor necrosis factor alpha (TNFα) in comparison to non-ICU patients were reported in patients with…”
Cheng, H., Wang, Y., & Wang, G. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25785 · Cited by 557 · cited 1×
“The accumulating clinical-epidemiological evidence about COVID-19 implies that SARS-CoV-2 associated ACE2 depletion is accompanied with a severe clinical course of disease in those clinical and epidemiological conditions that jeopardize the levels of ACE2 expression including older age, male sex, and medical condition…”
Pleiotropy and specificity: insights from the interleukin 6 family of cytokines
Murakami, M., Kamimura, D., & Hirano, T. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.027 · Cited by 533 · cited 1×
“This hyper-activation of NF-κB via the IL-6 Amp in the lungs induces a cytokine storm with subsequent ARDS that had been observed in severe COVID-19 patients [33,34].”
Santos, R. A. S., Ferreira, A. J., Verano‐Braga, T., & Bäder, M. (2012) · Journal of Endocrinology · doi:10.1530/joe-12-0341 · Cited by 523
Kuba, K., Imai, Y., Ohto‐Nakanishi, T., & Penninger, J. M. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.06.003 · Cited by 482 · cited 2×
“ACE2 enzyme is expressed in the heart, kidneys, testes, gastrointestinal tract and lungs [15,31].”
Complement as a target in COVID-19?
Risitano, A. M., Mastellos, D. C., Huber-Lang, M. S., Yancopoulou, D., Garlanda, C., Ciceri, F., & Lambris, J. D. (2020) · Nature reviews. Immunology · doi:10.1038/s41577-020-0320-7 · Cited by 480 · cited 1×
“complement pathway activation in severe COVID-19 [115].”
Guo, J., Huang, Z. Y. X., Lin, L., & Lv, J. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.120.016219 · Cited by 464 · cited 1×
“Therefore, in contrast to earlier clinical experts’ opinions, RAAS inhibitors should not be discontinued in stable cases of COVID-19 because the discontinuation of ACE inhibitors and ARBs may potentially have detrimental effects on these patients [14,37,38].”
Interactions of Transforming Growth Factor-β and Angiotensin II in Renal Fibrosis
Border, W. A., & Noble, N. A. (1998) · Hypertension · doi:10.1161/01.hyp.31.1.181 · Cited by 439
Gao, T., Hu, M., Zhang, X., Li, H., Zhu, L., Liu, H., Dong, Q., Zhang, Z., Wang, Z., Hu, Y., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1101/2020.03.29.20041962 · Cited by 435
Proinflammatory actions of angiotensins
Ruiz-Ortega, M., Lorenzo, O., Suzuki, Y., Rupérez, M., & Egido, J. (2001) · Current Opinion in Nephrology and Hypertension · doi:10.1097/00041552-200105000-00005 · Cited by 412 · cited 1×
“Ang II can activate the nuclear factor kappa B (NF-κB) pathway [24,25] via stimulation of the phosphorylation of the p65 subunit of NF-κB [26].”
Complement membrane attack on nucleated cells: resistance, recovery and non-lethal effects
Morgan, B. P. (1989) · Biochemical Journal · doi:10.1042/bj2640001 · Cited by 383
Wolf, G., Mueller, E., Stahl, R. A. K., & Ziyadeh, F. N. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116710 · Cited by 379
Regulation of Toll-like receptor–mediated inflammatory response by complement in vivo
Zhang, X., Kimura, Y., Fang, C., Zhou, L., Sfyroera, G., Lambris, J. D., Wetsel, R. A., Miwa, T., & Song, W. (2007) · Blood · doi:10.1182/blood-2006-12-063636 · Cited by 378 · cited 1×
“C5a, as the most potent complement derived mediator of inflammation in response to infections, increases production of IL-6, TNFα and IL-1 from Toll-Like Receptor (TLR-2, TLR-4, TLR-9) stimulated macrophages [113,114].”
The Renin-Angiotensin-Aldosterone System in Vascular Inflammation and Remodeling
Pacurari, M., Kafoury, R., Tchounwou, P. B., & Ndebele, K. (2014) · International Journal of Inflammation · doi:10.1155/2014/689360 · Cited by 376 · cited 1×
“This elegant system also plays a significant role in the promotion and maintenance of inflammation [18].”
Sodhi, C. P., Wohlford-Lenane, C., Yamaguchi, Y., Prindle, T., Fulton, W. B., Wang, S., McCray, P. B., Chappell, M. C., Hackam, D. J., & Jia, H. (2017) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00498.2016 · Cited by 332 · cited 2×
“Sodhi et al.[82] showed that activation of BKB1R enhances the neutrophil attraction to tissue by release of chemokine C-X-C motif chemokine 5 (CXCL5).”
Angiotensin-(1–7) inhibits growth of cardiac myocytes through activation of themasreceptor
Tallant, E. A., Ferrario, C. M., & Gallagher, P. E. (2005) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00941.2004 · Cited by 317
COVID-19: a case for inhibiting IL-17?
Pacha, O., Sallman, M. A., & Evans, S. E. (2020) · Nature reviews. Immunology · doi:10.1038/s41577-020-0328-z · Cited by 300
Josset, L., Menachery, V. D., Gralinski, L. E., Agnihothram, S., Sova, P., Carter, V. S., Yount, B. L., Graham, R. L., Baric, R. S., & Katze, M. G. (2013) · mBio · doi:10.1128/mbio.00165-13 · Cited by 299
ACE2/ANG-(1–7)/Mas pathway in the brain: the axis of good
Xu, P., Sriramula, S., & Lazartigues, E. D. (2010) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00222.2010 · Cited by 286 · cited 1×
“ACE2 can also directly metabolize Ang II to generate Ang-(1–7) [32].”
Cholesterol Crystals Induce Complement-Dependent Inflammasome Activation and Cytokine Release
Samstad, E. O., Niyonzima, N., Nymo, S. H., Aune, M. H., Ryan, L., Bakke, S. S., Lappegård, K. T., Brekke, O., Lambris, J. D., Damås, J. K., et al. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1302484 · Cited by 286
Kallikrein-kinin blockade in patients with COVID-19 to prevent acute respiratory distress syndrome
van de Veerdonk, F. L., Netea, M. G., van Deuren, M., van der Meer, J. W. M., de Mast, Q., Brüggemann, R. J. M., & van der Hoeven, H. (2020) · eLife · doi:10.7554/elife.57555 · Cited by 286 · cited 1×
“kinin B1 Receptor axis has been suggested by some authors [92,93].”
The first case of COVID-19 treated with the complement C3 inhibitor AMY-101
Mastaglio, S., Ruggeri, A., Risitano, A. M., Angelillo, P., Yancopoulou, D., Mastellos, D. C., Huber-Lang, M. S., Piemontese, S., Assanelli, A. A., Garlanda, C., et al. (2020) · Clinical Immunology · doi:10.1016/j.clim.2020.108450 · Cited by 281 · cited 1×
“cently, the compstatin-based complement C3 inhibitor AMY-101 was administered to a patient with ARDS due to COVID-19, in which very good clinical responses with a high level of safety were reported [116].”
C5a Negatively Regulates Toll-like Receptor 4-Induced Immune Responses
Hawlisch, H., Belkaid, Y., Bälder, R., Hildeman, D. A., Gerard, C. J., & Köhl, J. (2005) · Immunity · doi:10.1016/j.immuni.2005.02.006 · Cited by 277 · cited 1×
“C5a, as the most potent complement derived mediator of inflammation in response to infections, increases production of IL-6, TNFα and IL-1 from Toll-Like Receptor (TLR-2, TLR-4, TLR-9) stimulated macrophages [113,114].”
Distinct Immune Response in Two MERS-CoV-Infected Patients: Can We Go from Bench to Bedside?
Faure, E., Poissy, J., Goffard, A., Fournier, C., Kipnis, É., Titécat, M., Bortolotti, P., Martinez, L., Dubucquoi, S., Dessein, R., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0088716 · Cited by 249
Angiotensin-converting enzyme 2 inhibits lung injury induced by respiratory syncytial virus
Gu, H., Xie, Z., Li, T., Zhang, S., Lai, C., Zhu, P., Wang, K., Han, L., Duan, Y., Zhao, Z., et al. (2016) · Scientific Reports · doi:10.1038/srep19840 · Cited by 247 · cited 2×
“There are some trials regarding the efficacy and safety of this agent in clinicopathological settings related to ACE2 decrement such as congestive heart failure (CHF) [121], ARDS [122,123], and lung injury due to viral illness such as respiratory syncytial virus (RSV) [124].”
COVID-19 Infection and Circulating ACE2 Levels: Protective Role in Women and Children
Ciaglia, E., Vecchione, C., & Puca, A. A. (2020) · Frontiers in Pediatrics · doi:10.3389/fped.2020.00206 · Cited by 237 · cited 1×
“The accumulating clinical-epidemiological evidence about COVID-19 implies that SARS-CoV-2 associated ACE2 depletion is accompanied with a severe clinical course of disease in those clinical and epidemiological conditions that jeopardize the levels of ACE2 expression including older age, male sex, and medical condition…”
Sano, M., Fukuda, K., Kodama, H., Pan, J., Saito, M., Matsuzaki, J., Takahashi, T., Makino, S., Katō, T., & Ogawa, S. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m003128200 · Cited by 233 · cited 13×
“In a recent study, the first clinical evidence has shown that ACE inhibitors or ARB therapy in COVID-19 patients with hypertension were associated with a lower rate of disease severity, a trend toward lower IL-6 levels, and higher circulatory CD3+ and CD4+ T cells counts [39].”
InfluentialThomas, M. C., Pickering, R. J., Tsorotes, D., Koı̈tka, A., Sheehy, K., Bernardi, S., Toffoli, B., Nguyen‐Huu, T., Head, G. A., Fu, Y., et al. (2010) · Circulation Research · doi:10.1161/circresaha.110.219279 · Cited by 230
Schindler, R., Gelfand, J., & Dinarello, C. (1990) · Blood · doi:10.1182/blood.v76.8.1631.1631 · Cited by 228
Donoghue, M. (2003) · Journal of Molecular and Cellular Cardiology · doi:10.1016/s0022-2828(03)00177-9 · Cited by 214
Okusawa, S., Yancey, K. B., van der Meer, J. W., Endres, S., Lonnemann, G., Hefter, K., Frank, M., Burke, J. F., Dinarello, C. A., & Gelfand, J. A. (1988) · The Journal of Experimental Medicine · doi:10.1084/jem.168.1.443 · Cited by 213
Angiotensin II sustains brain inflammation in mice via TGF-β
Lanz, T. V., Ding, Z., Ho, P. P.-K., Luo, J., Agrawal, A., Srinagesh, H. K., Axtell, R. C., Zhang, H., Platten, M., Wyss‐Coray, T., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41709 · Cited by 202 · cited 1×
“For example, Ang II as an element from ACE/Ang II/AT1R induces TGFβ expression [22,117].”
Beyond lysis: how complement influences cell fate
Cole, D., & Morgan, B. P. (2003) · Clinical Science · doi:10.1042/cs20020362 · Cited by 199
Roles of Angiotensin Peptides and Recombinant Human ACE2 in Heart Failure
Basu, R., Poglitsch, M., Yogasundaram, H., Thomas, J., Rowe, B. H., & Oudit, G. Y. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.11.064 · Cited by 199 · cited 2×
“There are some trials regarding the efficacy and safety of this agent in clinicopathological settings related to ACE2 decrement such as congestive heart failure (CHF) [121], ARDS [122,123], and lung injury due to viral illness such as respiratory syncytial virus (RSV) [124].”
Cutting Edge: The NLRP3 Inflammasome Links Complement-Mediated Inflammation and IL-1β Release
Laudisi, F., Spreafico, R., Evrard, M., Hughes, T. R., Mandriani, B., Kandasamy, M., Morgan, B. P., Sivasankar, B., & Mortellaro, A. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1300489 · Cited by 198 · cited 4×
“Terminal products of the complement cascade can induce the production of cytokines such as TNF-α and IL-1 [98,101–104].”
InfluentialSu, Z., Zimpelmann, J., & Burns, K. D. (2006) · Kidney International · doi:10.1038/sj.ki.5001509 · Cited by 196 · cited 11×
“The loss of the modulatory effect of angiotensin-(1–7) via its binding to the Mas receptor (MasR) that attenuates inflammatory response may be a further contributing factor to the hyper-inflammation status of severe cases of COVID-19.”
InfluentialJiang, Y., Zhao, G., Song, N., Li, P., Chen, Y., Guo, Y., Li, J., Du, L., Jiang, S., Guo, R., et al. (2018) · Emerging Microbes & Infections · doi:10.1038/s41426-018-0063-8 · Cited by 195 · cited 1×
“The lung and spleen-induced pathological damages and inflammatory responses were alleviated through blockade of the C5a–C5aR axis in those transgenic mice [110].”
Recombinant human ACE2: acing out angiotensin II in ARDS therapy
Zhang, H., & BAKER, A. J. (2017) · Critical Care · doi:10.1186/s13054-017-1882-z · Cited by 181 · cited 10×
“An increment of the highly pro-inflammatory CCR6+ Th17 in CD4 T cells was reported in COVID-19 associated with ARDS [9].”
InfluentialMolecular Mechanisms of Inhibition of Vascular Growth by Angiotensin-(1-7)
Tallant, E. A., & Clark, M. A. (2003) · Hypertension · doi:10.1161/01.hyp.0000090322.55782.30 · Cited by 167
Inhibition of human lung cancer cell growth by angiotensin-(1-7)
Gallagher, P. E. (2004) · Carcinogenesis · doi:10.1093/carcin/bgh236 · Cited by 165
The Harmful Role of C5a on Innate Immunity in Sepsis
Ward, P. A. (2010) · Journal of Innate Immunity · doi:10.1159/000317194 · Cited by 159
Immunologic Effects of the Renin-Angiotensin System
Crowley, S. D., & Rudemiller, N. P. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016101066 · Cited by 155 · cited 1×
“It appears that activation of the RAAS system can induce inflammation in an independent mechanism of blood pressure through the AT1 receptor (AT1R) in the kidney and vasculature [19].”
Studies on the induction of pharmacological responses to des‐Arg9‐bradykinin in vitro and in vivo
Bouthillier, J., deBlois, D., & Marceau, F. (1987) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1987.tb11319.x · Cited by 153
Pan, Z. K., Zuraw, B. L., Lung, C.-C., Prossnitz, E. R., Browning, D. D., & Ye, R. D. (1996) · Journal of Clinical Investigation · doi:10.1172/jci119009 · Cited by 149
Parenti, A., Morbidelli, L., Ledda, F., Granger, H. J., & Ziche, M. (2001) · The FASEB Journal · doi:10.1096/fj.00-0503fje · Cited by 148 · cited 1×
“Activity of this receptor leads to expression of FGF-2 [83], and to increased levels of IL-1B [84] and MCP1 (Fig.”
Potential harmful effects of discontinuing ACE-inhibitors and ARBs in COVID-19 patients
Rossi, G. P., Sanga, V., & Barton, M. (2020) · eLife · doi:10.7554/elife.57278 · Cited by 147 · cited 1×
“Therefore, in contrast to earlier clinical experts’ opinions, RAAS inhibitors should not be discontinued in stable cases of COVID-19 because the discontinuation of ACE inhibitors and ARBs may potentially have detrimental effects on these patients [14,37,38].”
Angiotensin-converting enzyme 2 in acute respiratory distress syndrome
Imai, Y., Kuba, K., & Penninger, J. M. (2007) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-007-6228-6 · Cited by 131 · cited 10×
“An increment of the highly pro-inflammatory CCR6+ Th17 in CD4 T cells was reported in COVID-19 associated with ARDS [9].”
InfluentialGuilliams, M., Movahedi, K., Bosschaerts, T., VandenDriessche, T., Chuah, M., Hérin, M., Acosta‐Sanchez, A., Ma, L., Moser, M., Ginderachter, J. A. V., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.182.2.1107 · Cited by 131 · cited 1×
“Additionally, IL-10 is an anti-inflammatory cytokine that may be involved in the prevention of tissue damage [61,62].”
Skurk, T., van Harmelen, V., & Hauner, H. (2004) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000131266.38312.2e · Cited by 125
deBlois, D., Bouthillier, J., & Marceau, F. (1988) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1988.tb11487.x · Cited by 117
Human Lectins and Their Roles in Viral Infections
Mason, C. P., & Tarr, A. W. (2015) · Molecules · doi:10.3390/molecules20022229 · Cited by 116 · cited 1×
“By priming the immune system and enhancing clearances of viruses and virus-infected cells [111] ], the lectin pathway may also be involved in COVID-19 pathogenesis.”
Williams, M. E., & Balogun, R. A. (2013) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.04680513 · Cited by 103 · cited 1×
“Therefore, this option may be valuable in the treatment of severe COVID-19 [120].”
Complement-Induced Release of Monocyte Chemotactic Protein-1 From Human Smooth Muscle Cells
Torzewski, J., Oldroyd, R. G., Lachmann, P. J., Fitzsimmons, C. M., Proudfoot, D., & Bowyer, D. E. (1996) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.16.5.673 · Cited by 102 · cited 1×
“Terminal complement component C5b-9 induces release of IL-6 via activation of redox-sensitive transcription factor NF-κB and Activator Protein-1 (AP-1) [105] and Monocyte Chemoattractant protein-1 (MCP1) from vascular smooth muscle cells [106].”
Helderman, J. H. (1997) · PubMed · Cited by 102
David, S., Biancone, L., Caserta, C., Bussolati, B., CAMBI, V., & Camussi, G. (1997) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/12.1.51 · Cited by 98
Magalhães, G. S., Rodrigues‐Machado, M. D. G., Motta‐Santos, D., Silva, A. R., Caliari, M. V., Prata, L. O., Abreu, S. C., Rocco, P. R. M., Barcelos, L. S., Santos, R. A. S., et al. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13057 · Cited by 97
Tolouian, R., Vahed, S. Z., Ghiyasvand, S., Tolouian, A. C., & Ardalan, M. (2020) · Journal of Renal Injury Prevention · doi:10.34172/jrip.2020.19 · Cited by 93 · cited 1×
“kinin B1 Receptor axis has been suggested by some authors [92,93].”
Viedt, C., Hänsch, G. M., Brandes, R. P., Kübler, W., & Kreuzer, J. (2000) · The FASEB Journal · doi:10.1096/fj.00-0468fje · Cited by 91 · cited 1×
“Terminal complement component C5b-9 induces release of IL-6 via activation of redox-sensitive transcription factor NF-κB and Activator Protein-1 (AP-1) [105] and Monocyte Chemoattractant protein-1 (MCP1) from vascular smooth muscle cells [106].”
Kinin receptors in experimental inflammation
Marceau, F., Barabé, J., St-Pierre, S. A., & Regoli, D. C. (1980) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/y80-088 · Cited by 91 · cited 13×
“The active products of this system interact with two distinct G-protein coupled receptors, the bradykinin B1 receptor (BKB1R) and bradykinin B2 receptor (BKB2R); the main ligand of BKB1R is DABK and the ligand of BKB2R is BK [69,70].”
InfluentialdeBlois, D., Bouthillier, J., & Marceau, F. (1991) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1991.tb12300.x · Cited by 91
Polar Opposites: Erk Direction of CD4 T Cell Subsets
Chang, C., D’Souza, W. N., Ch’en, I. L., Pagès, G., Pouysségur, J., & Hedrick, S. Μ. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1103015 · Cited by 89 · cited 5×
“Additionally, IL-10 is an anti-inflammatory cytokine that may be involved in the prevention of tissue damage [61,62].”
InfluentialSoluble CR1 Therapy Improves Complement Regulation in C3 Glomerulopathy
Zhang, Y., Nester, C., Holanda, D. G., Marsh, H. C., Hammond, R. A., Thomas, L. J., Meyer, N. C., Hunsicker, L. G., Sethi, S. M., & Smith, R. J. (2013) · Journal of the American Society of Nephrology · doi:10.1681/asn.2013010045 · Cited by 86
Liang, B., Wang, X., Zhang, N., Yang, H., Bai, R., Liu, M., Bian, Y., Xiao, C., & Yang, Z. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000374047 · Cited by 86
Angiotensin-(1–7) activates growth-stimulatory pathways in human mesangial cells
Zimpelmann, J., & Burns, K. D. (2008) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.90437.2008 · Cited by 83
Kinin B1 receptors as a therapeutic target for inflammation
Qadri, F., & Bäder, M. (2017) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2018.1409724 · Cited by 82 · cited 2×
“Although several BKB1 antagonists have passed phase II clinical trials, none have been approved yet for clinical use [71].”
Al‐Maghrebi, M., Benter, I. F., & Diz, D. I. (2009) · Pharmacological Research · doi:10.1016/j.phrs.2008.12.008 · Cited by 80 · cited 2×
“Thus, Ang(1–7) per se has an anti-inflammatory effect and ameliorates inflammatory damages, as revealed in several animal studies [52,53].”
Zhang, J., Noble, N. A., Border, W. A., & Huang, Y. (2009) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00548.2009 · Cited by 79 · cited 2×
“Thus, Ang(1–7) per se has an anti-inflammatory effect and ameliorates inflammatory damages, as revealed in several animal studies [52,53].”
Jamaluddin, M., Meng, T., Sun, J., Boldogh, I. R., Han, Y., & Brasier, A. R. (2000) · Molecular Endocrinology · doi:10.1210/mend.14.1.0400 · Cited by 73
Ahmadian, E., Pennefather, P., Eftekhari, A., Heidari, R., & Eghbal, M. A. (2016) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2016.1207523 · Cited by 73 · cited 1×
“ACE2, Ang-(1–7) and Ang-(1–7) receptor Mas are the constituents of the other arm of the RAS system which counteracts and attenuates the effects of ACE-Ang II-AT1R axis [43,44].”
Haddad, J. J., Saadé, N. E., & Safieh‐Garabedian, B. (2003) · Cellular Signalling · doi:10.1016/s0898-6568(02)00075-x · Cited by 72
McLean, P. G., Perretti, M., & Ahluwalia, A. (1999) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0702743 · Cited by 70
Substituting Angiotensin-(1-7) to Prevent Lung Damage in SARS-CoV-2 Infection?
Peiró, C., & Moncada, S. (2020) · Circulation · doi:10.1161/circulationaha.120.047297 · Cited by 66
Fraga‐Silva, R. A., Silva, D. D., Montecucco, F., Mach, F., Stergiopulos, N., da Silva, R., & Santos, R. A. S. (2012) · Thrombosis and Haemostasis · doi:10.1160/th12-06-0396 · Cited by 66
A doubt of multiple introduction of SARS‐CoV‐2 in Italy: A preliminary overview
Giovanetti, M., Angeletti, S., Benvenuto, D., & Ciccozzi, M. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25773 · Cited by 63 · cited 1×
“The coronavirus infectious disease 2019 (COVID-19) that is spreading at the global scale is caused by a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), an enveloped single-stranded RNA virus belonging to the Coronaviridae family, genus beta-coronavirus [1].”
Kallikrein-Kinin System Mediated Inflammation in Alzheimers Disease In Vivo
Viel, T. A., & Buck, H. S. (2011) · Current Alzheimer Research · doi:10.2174/156720511794604570 · Cited by 63
Ehanire, T. E., Ren, L., Bond, J. E., Medina, M., Li, G. Q., Bashirov, L., Chen, L., Kokosis, G., Ibrahim, M. M., Selim, A. M., et al. (2014) · Journal of Molecular Medicine · doi:10.1007/s00109-014-1211-9 · Cited by 57 · cited 1×
“For example, Ang II as an element from ACE/Ang II/AT1R induces TGFβ expression [22,117].”
T helper cytokine patterns: defined subsets, random expression, and external modulation
Mosmann, T. R., Kobie, J. J., Lee, F. E.-H., & Quataert, S. A. (2009) · Immunologic Research · doi:10.1007/s12026-009-8098-5 · Cited by 54 · cited 1×
“Th-2 regulates immune responses by producing anti-inflammatory cytokines like IL-4, IL-5, IL-9 and IL-13 [60].”
A bradykinin (BK)1 receptor antagonist blocks capsaicin‐induced ear inflammation in mice
Mantione, C. R., & Rodriguez, R. (1990) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1990.tb12960.x · Cited by 49
Yu, X., Cui, L., Hou, F., Liu, X., Wang, Y., Wen, Y., Chi, C., Li, C., Liu, R., & Yin, C. (2017) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2017.3252 · Cited by 49
Verdecchia, P., Gentile, G., Angeli, F., & Reboldi, G. (2012) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944712444866 · Cited by 48
Yong-jun, G., Li, W., Wu, R., Xie, Q., & Cui, L. (2007) · Archives of Medical Research · doi:10.1016/j.arcmed.2007.07.010 · Cited by 46 · cited 1×
“ACE2, Ang-(1–7) and Ang-(1–7) receptor Mas are the constituents of the other arm of the RAS system which counteracts and attenuates the effects of ACE-Ang II-AT1R axis [43,44].”
Porreca, F., Vanderah, T. W., Guo, W., Barth, M., Dodey, P., Peyrou, V., Luccarini, J., Junien, J., & Pruneau, D. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.098368 · Cited by 44
Bradykinin receptors localized by quantitative autoradiography in kidney, ureter, and bladder
Manning, D. C., & Snyder, S. H. (1989) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.1989.256.5.f909 · Cited by 43 · cited 1×
“The active products of this system interact with two distinct G-protein coupled receptors, the bradykinin B1 receptor (BKB1R) and bradykinin B2 receptor (BKB2R); the main ligand of BKB1R is DABK and the ligand of BKB2R is BK [69,70].”
Chen, Y., Yang, C., Jin, N., Xie, Z., Tang, Y., Fei, L., Jia, Z., & Wu, Y. (2006) · European Journal of Immunology · doi:10.1002/eji.200636285 · Cited by 40
Albert-Weißenberger, C., Stetter, C., Meuth, S. G., Göbel, K., Bäder, M., Sirén, A., & Kleinschnitz, C. (2012) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2012.62 · Cited by 39
Brabykinin B1 Receptor Antagonism Is Beneficial in Renal Ischemia-Reperfusion Injury
Wang, P. H. M., Campanholle, G., Cenedeze, M. A., Feitoza, C. Q., Gonçalves, G. M., Landgraf, R. G., Jancar, S., Pesquero, J. B., Pacheco‐Silva, Á., & Câmara, N. O. S. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003050 · Cited by 38 · cited 4×
“It should be mentioned that IL-1B and TNFα-induced BKB1R expression is related to NF-κB activity [81].”
InfluentialLévesque, L., Larrivée, J., Bachvarov, D. R., Rioux, F., Drapeau, G., & Marceau, F. (1995) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1995.tb16390.x · Cited by 37
Severe hypertension with renal thrombotic microangiopathy: what happened to the usual suspect?
Laecke, S. V., & Biesen, W. V. (2017) · Kidney International · doi:10.1016/j.kint.2017.02.025 · Cited by 34 · cited 2×
“Furthermore, increased production of Ang II and activation of AT1R are accompanied with a pro-inflammatory response via activation of the complement cascade including C5a, C5b-9 [23].”
Selective Induction of Cardiovascular Responses to des-Arg 9 -Bradykinin by Bacterial Endotoxin
Marceau, F., Lussier, A., & St-Pierre, S. A. (2008) · Pharmacology · doi:10.1159/000137994 · Cited by 33
Bélichard, P., Loillier, B., Paquet, J. L., Luccarini, J. M., & Pruneau, D. (1996) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1996.tb15322.x · Cited by 27 · cited 13×
“The active products of this system interact with two distinct G-protein coupled receptors, the bradykinin B1 receptor (BKB1R) and bradykinin B2 receptor (BKB2R); the main ligand of BKB1R is DABK and the ligand of BKB2R is BK [69,70].”
InfluentialThe Role of the Complement System in Virus Infections
Spear, G. T., Hart, M. L., Olinger, G. G., Hashemi, F. B., & Saifuddin, M. (2001) · Current topics in microbiology and immunology · doi:10.1007/978-3-662-05783-4_12 · Cited by 25 · cited 1×
“The viral inactivation by the complement cascade involves virus uptake and clearance by phagocytic cells, coating virions resulting in prevention of attachment with their receptors, virus lysis by pore formation, and destruction of its membrane by membrane attack complex formation (C5b-9) [94].”
Wang, P. H. M., Cenedeze, M. A., Pesquero, J. B., Pacheco‐Silva, Á., & Câmara, N. O. S. (2006) · International Immunopharmacology · doi:10.1016/j.intimp.2006.07.031 · Cited by 23
Gheblawi, M., Wang, K., Viveiros, A., Nguyen, Q., Zhong, J., Turner, A. J., Raizada, M. K., Grant, M. B., & Oudit, G. Y. (2020) · Circulation Research · doi:10.1161/circresaha.120.317332 · Cited by 21
de Kimpe, S. J., Tielemans, W., Heuven-Nolsen, D. V., & Nijkamp, F. P. (1994) · European Journal of Pharmacology · doi:10.1016/0014-2999(94)90308-5 · Cited by 20
Barth, M., Bondoux, M., Luccarini, J., Peyrou, V., Dodey, P., Pruneau, D., Massardier, C., & Paquet, J. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm2016057 · Cited by 14 · cited 1×
“LF22-0542 (Safotibant) is a BKB1R antagonist with promising anti-inflammatory results [126,127].”
The kinin B1 receptor mediates alloknesis in a murine model of inflammation
Feng, J., Chen, Y., Xiong, J., Chen, X., Liang, J., & Ji, W. (2013) · Neuroscience Letters · doi:10.1016/j.neulet.2013.12.014 · Cited by 13
Many drugs for many targets: novel treatments for complement-mediated glomerular disease
Thurman, J. M. (2017) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfw228 · Cited by 13 · cited 2×
“Compstatin is a cyclic inhibitor of C3 cleavage [129] that may be considered in severe COVID-19.”
Bettaieb, A., Xi, Y., Hosein, E., Halmai, N. B., Bachaalany, S. M., Wiede, F., Pérez, S., Griffey, S. M., Sastre, J., Tiganis, T., et al. (2014) · Cell Communication and Signaling · doi:10.1186/1478-811x-12-13 · Cited by 13
Bradykinin-induced leukocyte– and platelet–endothelium interactions in the cerebral microcirculation
Waldner, M. J., Baethmann, A. J., Uhl, E., & Lehmberg, J. (2012) · Brain Research · doi:10.1016/j.brainres.2012.02.010 · Cited by 10
Bradykinin promotes Toll like receptor-4 expression in human gingival fibroblasts
Gutiérrez‐Venegas, G., Arreguín-Cano, J. A., & Bermúdez, C. H. (2012) · International Immunopharmacology · doi:10.1016/j.intimp.2012.07.021 · Cited by 10
Ren, T., He, H., Yu, X., Fan, J., Tan, J., & Liu, J. (2013) · PubMed · Cited by 2
Research works printed but not linked: 3
- Bm, 2020, COVID-19 induced Renin-Angiotensin System (RAS) imbalance may drive acute lung injury: the evidence and therapeutic options, BMJ, 368
- Gheblawi, 2020, Angiotensin Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System, Circ. Res.
- Gao, 2020, Highly pathogenic coronavirus N protein aggravates lung injury by MASP-2-mediated complement over-activation, medRxiv
Cited by
Sorted by citations
IL-6 in inflammation, autoimmunity and cancer
Hirano, T. (2021) · International Immunology · doi:10.1093/intimm/dxaa078 · Cited by 1,453
“Therefore, SARS-CoV-1 and SARS-CoV-2 infection activate both NF-κ B and STAT3, key elements of the IL-6 Amp, to cause cytokine storm (12, 13, 15, 349, 350).”
BackgroundHow COVID-19 induces cytokine storm with high mortality
Hojyo, S., Uchida, M., Tanaka, K., Hasebe, R., Tanaka, Y., Murakami, M., & Hirano, T. (2020) · Inflammation and Regeneration · doi:10.1186/s41232-020-00146-3 · Cited by 663
Rouzé, A., Martín‐Loeches, I., Póvoa, P. M. S. R., Makris, D. A., Artigas, A., Bouchereau, M., Lambiotte, F., Metzelard, M., Cuchet, P., Geronimi, C. B., et al. (2021) · Intensive Care Medicine · doi:10.1007/s00134-020-06323-9 · Cited by 388
Systemic racism, chronic health inequities, and COVID ‐19: A syndemic in the making?
Gravlee, C. C. (2020) · American Journal of Human Biology · doi:10.1002/ajhb.23482 · Cited by 390
Najjar, S., Najjar, A., Chong, D. J., Pramanik, B. K., Kirsch, C., Kuzniecky, R., Pacia, S. V., & Azhar, S. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-01896-0 · Cited by 292
Metadata
- Authors
- Mahmudpour, M., Roozbeh, J., Keshavarz, M., Farrokhi, S., & Nabipour, I.
- Affiliations
- Bushehr University of Medical Sciences (IR)
- Shiraz University of Medical Sciences (IR)
- Iranian Academy of Medical Sciences (IR)
- Corresponding author
- Nabipour, Iraj
- Venue
- Cytokine
- Publisher
- Elsevier BV
- Published
- 2020-09
- Volume
- 133
- Pages
- 155151
- ISSN
- 1043-4666 (ISSN-L)
- PMC
- PMC7260598
- OpenAlex
- W3030136428
- Cited by
- 461
- References
- 140
- Citations by year
- 2026: 8 · 2025: 18 · 2024: 47 · 2023: 61 · 2022: 104 · 2021: 168 · 2020: 52
- FWCI
- 4.55
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cytokine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Bushehr University of Medical Sciences
- Topics
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Keywords
- COVID-19 pandemic, cytokine storm, SARS-CoV-2, hyperinflammation, ACE2, renin-angiotensin-aldosterone system, Mas receptor, bradykinin B1 receptor, complement system, C5a, membrane attack complex, acute respiratory distress syndrome, intensive care unit patients, treatment options
- MeSH terms
- Betacoronavirus, Angiotensin-Converting Enzyme 2, COVID-19, SARS-CoV-2, Proto-Oncogene Mas, Bradykinin, Humans, Inflammation, Peptidyl-Dipeptidase A, Models, Molecular, Pneumonia, Viral, Proto-Oncogene Proteins, Renin-Angiotensin System, Complement C5a, Cytokines, Coronavirus Infections, Receptors, G-Protein-Coupled, Complement C5b, Pandemics, Spike Glycoprotein, Coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
